NFL Biosciences SA (EPA:ALNFL)

France flag France · Delayed Price · Currency is EUR
1.760
-0.028 (-1.57%)
Feb 21, 2025, 5:35 PM CET
-14.15%
Market Cap 17.08M
Revenue (ttm) 39.00
Net Income (ttm) -978.24K
Shares Out 9.71M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,929
Average Volume 21,964
Open 1.820
Previous Close 1.788
Day's Range 1.720 - 1.788
52-Week Range 1.612 - 3.280
Beta 1.45
RSI 41.73
Earnings Date Mar 28, 2025

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 2
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.